We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi
Read MoreHide Full Article
Tandem Diabetes Care, Inc. (TNDM - Free Report) recently unveiled its latest innovation, the Tandem Mobi, marking a significant milestone in the field of diabetes management. With this device’s U.S. commercial launch, Tandem aims to expand its durable insulin pump business and provide individuals living with diabetes unparalleled control and comfort in managing their condition.
A Few Words on Tandem Mobi
The Tandem Mobi is claimed to be the world's smallest durable automated insulin delivery system, setting a new benchmark in pump size and wearability. Its compact design, less than half the size of the t:slim X2 pump, offers users unprecedented convenience, fitting effortlessly into pockets or discreetly clipped onto clothing.
One of the most compelling aspects of the Tandem Mobi is its versatility in wearability, providing users with options that suit their lifestyle preferences. Whether worn on-body with an adhesive sleeve, discreetly clipped or slipped into a pocket, the Mobi ensures that users can manage their diabetes discreetly and comfortably, enhancing their quality of life.
Integrated Technology and Easy Access
The integration of Control-IQ technology, renowned for its ability to predict and prevent fluctuations in blood sugar levels, further enhances the appeal of the Tandem Mobi. This advanced feature, coupled with compatibility with the Dexcom G6 CGM system, empowers users with real-time insights and automatic adjustments to optimize glucose levels.
Orders will be processed on a first-come, first-served basis, with initial shipments to users who meet specific eligibility requirements.
Image Source: Zacks Investment Research
Market Prospects
According to a Mordor Intelligence report, the Wearable Diabetes Devices Market is booming, estimated at $11 billion in 2024 and projected to hit $18 billion by 2029, with a CAGR exceeding 10%. Due to their convenience, ability to provide real-time data and potential to improve glycemic control, wearable devices for diabetes management are becoming increasingly popular.
Share Price Performance
Shares of Tandem Diabetes have plunged 43.1% over the past year against the 1.6% rise of the industry.
Zacks Rank and Key Picks
TNDM currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Stryker (SYK - Free Report) .
Universal Health Services, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 4.4% for 2024. UHS’ earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 5.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UHS’ shares have risen 6.5% in the past year compared with the industry’s 11.8% rise.
Integer Holdings, presently carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 54.8% in the past year against the industry’s 3.5% decline.
Estimates for Stryker’s 2024 earnings per share have increased from $11.53 to $11.84 in the past 30 days. Shares of the company have moved 28.8% north in the past year compared with the industry’s rise of 4%. SYK carries a Zacks Rank #2 currently.
SYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.1%. In the last reported quarter, it delivered an earnings surprise of 5.8%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi
Tandem Diabetes Care, Inc. (TNDM - Free Report) recently unveiled its latest innovation, the Tandem Mobi, marking a significant milestone in the field of diabetes management. With this device’s U.S. commercial launch, Tandem aims to expand its durable insulin pump business and provide individuals living with diabetes unparalleled control and comfort in managing their condition.
A Few Words on Tandem Mobi
The Tandem Mobi is claimed to be the world's smallest durable automated insulin delivery system, setting a new benchmark in pump size and wearability. Its compact design, less than half the size of the t:slim X2 pump, offers users unprecedented convenience, fitting effortlessly into pockets or discreetly clipped onto clothing.
One of the most compelling aspects of the Tandem Mobi is its versatility in wearability, providing users with options that suit their lifestyle preferences. Whether worn on-body with an adhesive sleeve, discreetly clipped or slipped into a pocket, the Mobi ensures that users can manage their diabetes discreetly and comfortably, enhancing their quality of life.
Integrated Technology and Easy Access
The integration of Control-IQ technology, renowned for its ability to predict and prevent fluctuations in blood sugar levels, further enhances the appeal of the Tandem Mobi. This advanced feature, coupled with compatibility with the Dexcom G6 CGM system, empowers users with real-time insights and automatic adjustments to optimize glucose levels.
Orders will be processed on a first-come, first-served basis, with initial shipments to users who meet specific eligibility requirements.
Image Source: Zacks Investment Research
Market Prospects
According to a Mordor Intelligence report, the Wearable Diabetes Devices Market is booming, estimated at $11 billion in 2024 and projected to hit $18 billion by 2029, with a CAGR exceeding 10%. Due to their convenience, ability to provide real-time data and potential to improve glycemic control, wearable devices for diabetes management are becoming increasingly popular.
Share Price Performance
Shares of Tandem Diabetes have plunged 43.1% over the past year against the 1.6% rise of the industry.
Zacks Rank and Key Picks
TNDM currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Stryker (SYK - Free Report) .
Universal Health Services, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 4.4% for 2024. UHS’ earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 5.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UHS’ shares have risen 6.5% in the past year compared with the industry’s 11.8% rise.
Integer Holdings, presently carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 54.8% in the past year against the industry’s 3.5% decline.
Estimates for Stryker’s 2024 earnings per share have increased from $11.53 to $11.84 in the past 30 days. Shares of the company have moved 28.8% north in the past year compared with the industry’s rise of 4%. SYK carries a Zacks Rank #2 currently.
SYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.1%. In the last reported quarter, it delivered an earnings surprise of 5.8%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.